InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Clinuvel Pharmaceuticals Limited (ASX:CUV)

ALERT: Price-sensitive ASX Announcement for CUV
Current share price for CUV : $9.750 0.16 (1.67%)+
Announcement
Release
30 Jul 2026 8:57AM
Price at Release
$9.590
Full Release
download
Summary
CLINUVEL PHARMACEUTICALS LTD provided a commercial update on vitiligo treatments, focusing on their product SCENESSE® (afamelanotide) in combination with narrowband UVB (NB-UVB) therapy. SCENESSE® is being developed as a systemic repigmentation therapy, differentiating it from JAK inhibitors which are more limited in body surface area treatment. The company has completed trials (CUV105) that show promising results in repigmentation, particularly with extensive vitiligo cases. CLINUVEL is preparing for market expansion in North America, anticipating new studies and infrastructure expansion to support the commercialization of SCENESSE® in vitiligo treatment.
Key Points
  • CLINUVEL shared a commercial update on vitiligo.
  • SCENESSE® is developed for systemic repigmentation.
  • Comparative trials show improved efficacy over monotherapy.
  • North American infrastructure expansion for market entry.
  • Upcoming pivotal study CUV107 set to begin in 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.